Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.

AUTOR(ES)

Stern, D F

RESUMO

p185, the product of the neu/erbB2 proto-oncogene, is oncogenically activated by a point mutation that substitutes glutamic acid for valine in the transmembrane domain of the protein. We have found that the transforming form of p185 differs from its normal counterpart in inducing increased tyrosine phosphorylation of other proteins in vivo and in having a much shorter half-life. These results support the model that the transforming p185 resembles a ligand-activated receptor.

Documentos Relacionados

• p185neu is expressed in yolk sac during rat postimplantation development.
• EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
• Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
• The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling
• A subdomain in the transmembrane domain is necessary for p185neu* activation.